THERAPY DOSSIER · th-c608d07e98b8

Rosamultin

Nutraceutical · No ChEMBL record under 'rosamultin' (ursane-type triterpenoid glycoside). ClinicalTrials.gov returned no records.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: No ChEMBL record under 'rosamultin' (ursane-type triterpenoid glycoside). ClinicalTrials.gov returned no records.
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32598190 ↗2020Reported benefit

Rosamultin Attenuates Acute Hypobaric Hypoxia-Induced Bone Injuries by Regulation of Sclerostin and Its Downstream Signals.

RatOtherPretreatment before hypobaric hypoxia exposure

Model: Acute hypobaric hypoxia simulating high altitude, causing bone damage and abnormal bone remodelling

Rosamultin pretreatment reduced hypobaric hypoxia induced oxidative stress and inflammation, improved bone metabolic abnormalities and rebalanced bone remodelling by suppressing sclerostin and activating Wnt/beta-catenin signalling.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…